Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) Short Interest Update

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) was the recipient of a significant decline in short interest during the month of June. As of June 30th, there was short interest totaling 2 shares, a decline of 98.5% from the June 15th total of 137 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily volume of 2,784 shares, the days-to-cover ratio is presently 0.0 days.

Enzon Pharmaceuticals Price Performance

Enzon Pharmaceuticals stock remained flat at $4.40 during mid-day trading on Friday. 4,182 shares of the company’s stock traded hands, compared to its average volume of 970. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.16 and a current ratio of 2.01. Enzon Pharmaceuticals has a one year low of $1.50 and a one year high of $11.10. The business has a 50-day moving average of $5.55 and a two-hundred day moving average of $5.68. The stock has a market cap of $3.26 million, a PE ratio of -0.64 and a beta of -0.05.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last issued its earnings results on Monday, May 4th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter. The firm had revenue of $86.54 million for the quarter.

Enzon Pharmaceuticals Company Profile

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.